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Tuberculosis (TB) is a major health problem in the Western 
Cape, with a rising incidence which now exceeds 900 per  
100 000 population.1 In this setting, nosocomial transmission 
of TB is a potential risk, particularly to HIV-infected or other 
immunocompromised patients. Nosocomial outbreaks of TB 
are usually noted initially because of increasing rates of TB 
among previously hospitalised patients, and subsequently 
confirmed by molecular typing of Mycobacterium tuberculosis 
isolates. However, in high-incidence areas, detection is 
hampered by the high background level of TB within 
communities, delays in development of symptoms in 
immunocompetent persons, and the existence of multiple TB 
service providers. In South Africa, nosocomial outbreaks of TB 
have been documented among HIV-infected patients at Sizwe 
Tropical Disease Hospital,2 neonates in a kangaroo mother 
care unit,3 and in a rural hospital at Tugela Ferry.4 This latter 
outbreak involved the spread of extensively drug-resistant 
(XDR) TB (defined as resistance to isoniazid, rifampicin, any 
fluoroquinolone and at least 1 of 3 injectable second-line 
drugs)5 among a large number of HIV-infected patients with 
rapidly fatal outcomes. Detection of these outbreaks was 
facilitated by the vulnerable status of the patients, which 
resulted in rapid progression to disease, drug-resistant status 
of infecting strains, and the relative isolation of the hospitals in 
terms of geography or timing of exposure. It is likely that cases 
of nosocomial TB remain undetected in other situations.
Multidrug-resistant (MDR)-TB (defined as TB resistant to 
both isoniazid and rifampicin) is more difficult to treat than 
drug-sensitive TB, requires longer courses of more toxic drugs, 
and has poorer outcomes. Therefore, there is particular concern 
regarding the transmission of MDR-TB within health care 
facilities in South Africa. Rapid diagnosis and rapid institution 
of effective anti-TB treatment, combined with appropriate 
infection control measures, are key factors in the prevention of 
nosocomial transmission of TB.
We aimed to determine the in-hospital delays in diagnosis 
and treatment of patients with MDR-TB at Tygerberg Hospital 
(an academic tertiary care hospital) over the period of 1 year, to 
estimate the potential for nosocomial transmission.
Methods
This was a descriptive study based on retrospective review 
of patient records and laboratory data, and included all adult 
patients (>13 years) in whom TB culture and susceptibility 
testing confirmed MDR-TB on specimens submitted to 
Tygerberg Hospital National Health Laboratory Service 
(NHLS) between 1 January and 31 December 2007. The 
decision to request TB culture and drug susceptibility testing 
(DST) was made by the attending clinician. Culture and 
susceptibility testing was performed in an automated liquid 
culture system (MGIT, Becton Dickinson, Sparks, Maryland) 
and confirmation of M. tuberculosis was by a rapid molecular 
method.6 All tests were carried out in an accredited laboratory 
using appropriate safety precautions.
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Background. Tuberculosis (TB) is a major health problem in the 
Western Cape, with an incidence exceeding 900 per 100 000 
people. Nosocomial transmission of TB, and particularly 
drug-resistant TB, is a potential risk that may be undetected. 
Rapid diagnosis and rapid institution of effective anti-TB 
treatment, combined with appropriate infection control 
measures, are essential to prevent nosocomial transmission of 
TB. To estimate the potential for nosocomial transmission, we 
aimed to determine the in-hospital delays in diagnosis and 
treatment of patients with multidrug-resistant (MDR)-TB at a 
tertiary care hospital.
Methods. A descriptive study, based on retrospective review 
of patient records and laboratory data, including all adult 
patients (>13 years) where TB culture and susceptibility 
testing confirmed MDR-TB on specimens submitted to 
Tygerberg Hospital’s National Health Laboratory Service 
(NHLS) laboratory in 2007.
Results. Thirty-one patients with MDR-TB were identified. 
The median laboratory turnaround time (TAT) from collection 
of specimen to confirmation of MDR-TB was 40 days, 
while the median time from the time of first presentation at 
Tygerberg Hospital to institution of MDR treatment was 44 
days. Twenty patients were considered infectious during their 
hospital stay, generating 345 inpatient infectious days.
Conclusions. The study suggests that there is an ongoing 
substantial risk for nosocomial transmission of MDR-TB at 
Tygerberg Hospital. We propose improvements, including 
the use of rapid drug susceptibility testing. The consistent 
application of infection control measures to prevent 
nosocomial spread of TB, including MDR-TB, remains vital.
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Patient records were retrieved and data extracted using 
a standardised form. The dates of any outpatient visits 
and inpatient admissions were recorded; results of TB 
investigations, including DST results, and the dates on which 
such results were available, were obtained from the laboratory 
information system databases of the NHLS laboratories at 
Tygerberg and Green Point. Use of the Green Point database 
provided access to the results of any specimens sent from other 
hospitals or clinics in the 3 months preceding presentation at 
Tygerberg Hospital.
Clinical failure was defined as persistence of symptoms 
after 2 months of first-line TB therapy. Microbiological failure 
was defined as failure of smear conversion (in those initially 
smear-positive) after 2 months of first-line TB therapy. For the 
calculation of in-hospital infectivity, patients were assumed to 
be infectious from the date of admission until the date when 
they started MDR treatment.
The study was approved by the Committee for Human 
Research of the Faculty of Health Sciences, University of 
Stellenbosch (N08/03/064). The Department of Infectious 
Diseases at Tygerberg Hospital undertook to contact 
all patients discharged home who lacked evidence of 
commencement of MDR treatment.
Results
From the 355 adults with culture-confirmed tuberculosis in 
whom DST was performed, 31 patients with MDR-TB were 
identified and folders retrieved; there were 21 males and 10 
females, and their median age was 32 years (range 18 - 53 
years). The majority of patients (20/31) were referred to 
Tygerberg Hospital (TBH) and originated from a variety of 
sources (Table I). Four patients were already attending the 
hospital’s Infectious Diseases Clinic, referred initially in most 
cases to access antiretroviral therapy (ART). One staff member 
presented to the occupational health clinic.
The majority (26/31) of patients were admitted. Only 5 were 
seen exclusively on an outpatient basis, including the staff 
member seen at the occupational health clinic, an 18-year-old 
known MDR patient receiving chronic care from the paediatric 
service, a known MDR patient referred for surgical assessment, 
a known MDR defaulter who self-referred, and 1 patient 
diagnosed with TB in the emergency ward, where the duration 
of her stay was unclear.
Five patients (included in the 9 referred from other hospitals) 
were referred from G F Jooste Hospital to the Khayelitsha 
District Hospital, located within the TBH complex. Four of 
these 5 patients were either known or suspected MDR patients 
who were awaiting placement in the MDR section of Brooklyn 
Chest Hospital (BCH).
Presence of known risk factors for MDR-TB
Six patients were known to have MDR-TB at the time of 
referral/presentation and were referred with complications of 
TB (2), for assessment for surgery (1), to await placement at 
BCH (1) or self-referred (1). One additional patient had been 
treated by the paediatric service for MDR-TB for a number of 
years.
MDR-TB was listed as part of the initial differential 
diagnosis in 8 (32%) of the remaining 25 patients. All 8 had 
evidence of clinical or microbiological failure at the time of 
presentation. An additional 4 patients had evidence of clinical 
or microbiological failure on presentation, but MDR-TB was 
not listed in the differential diagnosis. It was not possible 
to determine retrospectively any specific reasons for the 
requesting of DSTs in the remaining 13 patients.
Eighteen (58%) of the 31 patients gave a history of previous 
TB; in 4 (13%) this was their first episode of TB, and in 9 
(29%) no details were recorded. Microbiological details of 
the previous episode of TB were not available in most cases 
(susceptibility results available only in 5 known MDR patients, 
while 2 other patients had previous culture-proven TB without 
susceptibility testing, and 1 patient had been shown to be 
smear-negative on completion of previous therapy).
In 2 cases, the patients reported previous contact with a 
person with known MDR-TB. One of these cases was one of 
the 6 patients known to have MDR-TB at presentation to TBH. 
It was not possible to assess whether patients had previously 
defaulted from TB treatment, as this information was seldom 
recorded.
HIV co-infection
HIV status was unknown in 4 patients.  Of the 27 patients 
whose HIV status was known, 16 (59%) were HIV negative and 
11 (41%) were HIV positive. At the time of diagnosis of MDR-
TB, 7 HIV-positive patients were receiving or had previously 
received ART.
Site of infection
Twenty-six patients (84%) had pulmonary TB (PTB), while 5 
had extra-pulmonary TB, including 3 with pleural disease, 
1 with arthritis and 1 with lymphadenitis.  Of the patients 
with pleural TB, 1 was considered infectious owing to a 
broncho-pulmonary fistula with acid-fast bacilli (AFB) seen on 
microscopy of the pleural fluid. Twenty (77%) of the 26 patients 
with PTB  were smear-positive.
Laboratory turnaround time
The median laboratory turnaround time (TAT) from 
collection of specimen to confirmation of MDR-TB was 40 
days (minimum 25 days, maximum 101 days, inter-quartile 
range (IQR) 29 - 62 days). The median TAT for second-line 
susceptibility testing was (an additional) 42 days, with a 
minimum of 30 days, maximum of 58 days and IQR of 35 - 46 
Table I. Origin of adult multidrug-resistant tuberculosis 
(MDR-TB) patients at TBH in 2007
Origin      N %
Day hospital/community health centre/TB clinic   7   23
Other hospital (not TB hospital)    9   29
General practitioner     4   13
TBH Infectious Diseases Clinic    4   13
TBH Occupational Health Clinic    1     3
TBH Paediatric TB Clinic     1     3
Self-referred      2     6
Unknown      3   10
Total     31 100
ORIGINAL ARTICLES
440 July 2010, Vol. 100, No. 7  SAMJ
days. Only 7/31 (23%) patients had MDR-TB confirmed by 
laboratory testing within 30 days.
Second-line susceptibility testing and XDR-TB
Isolates from 20 patients had second-line susceptibility 
testing with varying numbers of isolates being tested against 
each drug (Table II). Resistance rates ranged from 5% for 
ethionamide to 46% for ethambutol. Resistance rates to 
amikacin and ofloxacin were 19% and 25% respectively.
Results from 3 patients demonstrated resistance to ofloxacin 
and amikacin, i.e. XDR-TB; 2 had known MDR-TB, and 1 had 
a history of previous TB and subsequently died of presumed 
HIV encephalopathy (see following section). Of the remaining 
17 patients, XDR was excluded in 10, while 2 showed resistance 
to an additional agent without fulfilling criteria for XDR, and 
testing was incomplete in 5.
Mortality
Five patients died in TBH within 2 weeks of admission, all 
before diagnosis of MDR-TB (crude mortality rate 16%); 2 
were HIV positive with advanced disease, and 3 were HIV 
negative. One HIV-negative patient who had been diagnosed 
5 months previously at TBH with TB arthritis was re-admitted 
shortly before death with PTB. Drug susceptibility testing of 
the respiratory specimen confirmed MDR-TB (and excluded 
XDR-TB). As DST was not performed on the original tissue 
specimen, it was not possible to confirm whether he had MDR-
TB initially.
Another HIV-negative patient was already under 
investigation at a peripheral clinic for drug-resistant TB. 
Although MDR results were available 49 days prior to his 
death, no MDR treatment had been started. His isolate was also 
resistant to ethambutol and ofloxacin, but the diagnosis of XDR 
could not be confirmed or excluded since no further testing 
was done.
One HIV-positive patient who died of presumed HIV 
encephalopathy had XDR-TB. There was no evidence of central 
nervous system (CNS) tuberculosis on CSF examination and 
culture or on CT scan prior to death.
Of the remaining 2 patients who died, XDR-TB was excluded 
in one and second-line testing was not carried out for the other.
Time to institution of MDR treatment at TBH
Ten patients were not eligible to start MDR treatment as they 
were already on MDR treatment at presentation (5) or died 
before the diagnosis of MDR-TB (5). Of the remaining 21 
patients, 10 were started on MDR treatment at TBH and 11 
were discharged on standard TB therapy (6) or transferred to 
BCH on standard TB therapy (5). Among the 10 patients with 
known date of starting MDR treatment, the median time to 
institution of treatment from the time of first presentation at 
TBH was 44 days (range 5 - 187 days).
Timing of initiation of MDR treatment in relation to 
availability of DST results
The time period between the availability of DST results 
confirming MDR-TB and the initiation of MDR treatment 
was calculated. For this calculation, results from specimens 
submitted from other institutions in the 3 months preceding 
presentation at Tygerberg Hospital were included (Table III).
Four patients were started on MDR treatment empirically 
based on clinical grounds, prior to the availability of DST 
results, supported by histological results (1 case) and by rapid 
molecular testing (1 case) accessed through research studies, as 
rapid molecular testing was not available as a diagnostic test in 
NHLS laboratories at the time.
Six patients were started on MDR treatment after DST results 
became available. In 3 patients, there was a delay of more than 
30 days between availability of DST results and initiation of 
MDR-TB treatment.
Period of in-hospital infectivity (TBH only)
Patients were assumed to be infectious from the date of 
admission until they started MDR treatment. Twenty patients 
were considered infectious, as those patients already on MDR 
treatment (4), patients with extra-pulmonary TB (3) and 
patients treated as outpatients (4) were excluded. These 20 
patients generated 345 inpatient infectious days averaging 
17 days per patient. It proved impossible to determine 
retrospectively whether appropriate infection control measures 
including placement in an individual room or the use of 
personal protective equipment such as N95 respirators (masks) 
were applied to suspected or confirmed MDR-TB patients.
Laboratory cross-contamination
No evidence of laboratory cross-contamination was found. 
There was no clustering of MDR cases within the laboratory. 
In all patients, TB was confirmed by correlation with clinical 
findings, microscopy or histology results, or by isolation of 
mycobacteria from other specimens. However, susceptibility 
testing was not usually carried out on more than one specimen 
per patient, and no molecular fingerprinting tests were carried 
out.
Table II. Second-line susceptibility test results of 
submitted isolates
   No. resistant/
Antimicrobial agent  No. tested       %
Ethambutol  12/26*        46
Amikacin   3/16        19
Ofloxacin   5/20        25
Ethionamide  1/19          5
*An additional 6 isolates were tested for ethambutol susceptibility, but not for second-
line agents.
Table III. Timing of initiation of treatment for multidrug-
resistant tuberculosis (MDR-TB) in relation to the 
availability of drug susceptibility testing (DST) results
      Exact
    No. of  timing
Number of days   patients  (days)
>30 days before results available 4  33, 33, 34, 95
0 - 7 days after results available 1  4
7 - 30 days after results available 2  13, 25
>30 days after results available 3  86, 98, 132
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Discussion
This small group of 31 patients with culture-confirmed MDR-
TB at a single tertiary care institution in 2007 generated 345 
inpatient infectious days, corresponding to one infectious MDR 
patient in the hospital almost every day of the year. There were 
also considerable in-hospital delays in the microbiological 
diagnosis of MDR-TB (median 40 days) and the initiation of 
MDR treatment (median 44 days from first presentation at 
TBH). However, the accuracy of this latter finding is limited by 
lack of data, as the date of commencement of MDR treatment 
was available for only 10 of 21 eligible patients, reflecting that 
many patients were discharged or transferred prior to the 
availability of laboratory results.
Only 23% of DST results were available within 30 days,7 
a target suggested by the Centers for Disease Control and 
Prevention (CDC) prior to recent concerns about the increasing 
prevalence of drug resistance. While these TATs may not be 
an accurate reflection of laboratory performance, as DST is 
sometimes only requested by clinicians some time after receipt 
of positive culture results, it suggests that current phenotypic 
methods of DST, including automated methods, are inadequate 
in situations of increasing drug resistance. Rapid DST should 
therefore be more widely available to expedite management of 
suspected MDR-TB patients, and possibly for all hospitalised 
PTB patients at the time of diagnosis. At the time of the study, 
second- and third-line DST was not routinely performed for all 
MDR patients, making interpretation of additional resistance 
patterns impossible.  Provincial policy has subsequently been 
amended to allow for automatic second-line testing for all 
MDR isolates.
While a shorter laboratory TAT can accelerate diagnosis and 
initiation of treatment, failure of health care workers to respond 
to laboratory results is another source of delay. The long delay 
of more than 1 month in 3 of 10 patients with known date 
of starting treatment is of concern. Part of this delay could 
be because clinicians were unaware of or unable to access 
the results of specimens submitted from other institutions. 
However, lack of patient co-operation might have contributed 
to delays, e.g. if a patient failed to return for follow-up at a 
peripheral hospital or clinic.
Given the slow laboratory TAT, it is not surprising that 
that the period of potential in-hospital infectivity was high. 
The figure of 345 inpatient infectious days is likely to be an 
underestimate of infectivity, as patients were assumed to 
become non-infectious immediately on commencement of 
MDR treatment. While the implementation of appropriate 
infection control measures could mitigate the possibility 
of nosocomial transmission, it was not possible to assess 
such measures retrospectively.  However, infection control 
measures are inconsistently applied in this setting8 and there is 
consequently a considerable risk for nosocomial transmission 
of MDR-TB.
The study included only those MDR-TB cases confirmed on 
culture at TBH, excluding those diagnosed elsewhere, as well 
as those treated empirically for MDR-TB. However, there was 
no alternative record of MDR-TB patients at TBH (personal 
communication, Infection Prevention and Control Unit), 
highlighting a shortcoming in the current system of MDR 
management. In addition, since culture and DST are performed 
only for a minority of TB cases, it is likely that this study 
under-estimates the number of cases of MDR-TB.
The present study did not include patients with rifampicin 
mono-resistance, although this is recently of increasing 
concern in the Western Cape. It was not practical to compare 
laboratory-based resistance rates from previous years because 
the changing pattern of DST requesting, with an increase 
in the number of DST requests, is likely to introduce bias 
and complicate interpretation. Limiting the study to a single 
institution also made it difficult to analyse patients who 
frequently move between institutions within the wider health 
care system.
The study suggests that there is an ongoing substantial risk 
for nosocomial transmission of MDR-TB at one local tertiary 
institution. While the incidence of drug-resistant TB may be 
less at primary- or secondary-level hospitals, they are likely 
to face similar delays in microbiological diagnosis. Steps that 
could be taken to reduce delays in diagnosis include the use of 
rapid DST, and the provision of improved access for clinicians 
to national or provincial laboratory information systems 
to facilitate retrieval of results from other institutions. The 
consistent application of infection control measures to prevent 
nosocomial spread of TB (including MDR-TB) remains vital.
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